SARS CoV 2 News and Research

RSS

Iron dysregulation identified as potential trigger for long COVID

Problems with iron levels in the blood and the body's ability to regulate this important nutrient as a result of SARS-CoV-2 infection could be a key trigger for long COVID, new research has discovered.

4 Mar 2024

How long do cognitive and memory dysfunctions persist after SARS-CoV-2 infection?

Whether cognitive deficits can be measured after severe acute respiratory syndrome (SARS-CoV-2) infection.

4 Mar 2024

Broad-spectrum neutralizing antibody mAb-39 targets conserved S2 epitope in SARS-CoV-2

The ongoing COVID-19 pandemic caused by SARS-CoV-2 has caused serious damage to public health and the global economy, and one strategy to combat COVID-19 has been the development of broadly neutralizing antibodies for prophylactic and therapeutic use.

1 Mar 2024

COVID-19's lasting mark: Long-term smell and taste loss

Study reveals prolonged olfactory and gustatory dysfunction in some COVID-19 recoverees, highlighting a need for better clinical support and understanding of long-term effects.

29 Feb 2024

Corticosteroids may restore sense of smell in COVID-19 patients

COVID-19 is known to cause loss of smell in certain patients. While this symptom is generally temporary, approximately 10% of patients may suffer from it for 6 months or more.

29 Feb 2024

Higher COVID-19 death risk found in sickle cell disease and trait patients

UdeM's Stéphanie Forté and co-researchers in Canada and Brazil have shown how people with sickle cell disease or sickle cell trait have a higher chance of dying from COVID-19 than the general population.

29 Feb 2024

Association of estrogen-containing menopause hormonal therapy with COVID-19 mortality

Researchers evaluated coronavirus disease 2019 (COVID-19)-related mortality among perimenopausal women.

29 Feb 2024

Unlocking coronavirus structure through M protein research

For centuries, coronaviruses have triggered health crises and economic challenges, with SARS-CoV-2, the coronavirus that spreads COVID-19, being a recent example.

28 Feb 2024

Scientists uncover a new doorway for SARS-CoV-2 into human cells

Research identifies the human transferrin receptor as an alternative pathway for SARS-CoV-2 infection, offering potential new targets for COVID-19 therapies.

27 Feb 2024

Study shows the benefits of locally administered intranasal live-attenuated SARS-CoV-2 vaccine

Rocketvax AG, together with the German Research Foundation (DFG), has financially supported a study carried out as part of a joint project of the Swiss National Science Foundation (SNSF, National Research Program "Covid-19," NRP 78) and the German Research Foundation (DFG) "Recoding the SARS-CoV-2 Genome - A Multidisciplinary Approach to Generate Live-Attenuated Coronavirus Vaccines."

27 Feb 2024

Vaping increases susceptibility to COVID-19 infection, study finds

Vapers are susceptible to infection by SARS-CoV-2, the virus that spreads COVID-19 and continues to infect people around the world, a University of California, Riverside, study has found.

26 Feb 2024

Study reveals early death predictors in COVID-19 patients with cardiac injury

Announcing a new article publication for Cardiovascular Innovations and Applications journal. The activation of immune and thrombotic biomarkers at admission, and their ability to predict cardiac injury and mortality patterns in COVID-19, remains unclear.

26 Feb 2024

Study reveals how long COVID can affect brain function through vascular disruption

The neurological response to coronavirus disease 2019 (COVID-19) may be due to brain-brain barrier (BBB) disruption.

26 Feb 2024

SARS-CoV-2-infection and vaccine-induced antibodies wane initially but stabilize for lasting protection

A study published in Immunity shows that antibody responses to SARS-CoV-2 infection and vaccination are long-lasting, with an initial decline followed by stabilization after seven to nine months, highlighting the effectiveness of mRNA vaccines and the importance of hybrid immunity.

25 Feb 2024

Identifying antiviral protein IFN-γ as a potential biomarker for Long COVID

SARS-CoV-2 triggers the production of the antiviral protein IFN-γ, which is associated with fatigue, muscle ache and depression. New research shows that in Long COVID patients, IFN-y production persists until symptoms improve, highlighting a potential biomarker and a target for therapies.

24 Feb 2024